| Zacks Company Profile for Endonovo Therapeutics, Inc. (ENDV : OTC) |
|
|
| |
| • Company Description |
| Endonovo Therapeutics, Inc. is a biotechnology company which is engaged in developing a bioelectronic approach to regenerative medicine. The company's Immunotronics(TM) platform is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation and necrosis, and the promotion of regeneration. Endonovo's Cytotronics(TM) platform provides method of expanding and manipulating cells using simulated microgravity and Time-Varying Electromagnetic Fields for tissue engineering and cell therapies. Endonovo Therapeutics, Inc. is headquartered in Woodland Hills, California.
Number of Employees: |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $0.00 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 1,018,549 shares |
| Shares Outstanding: 1,206.61 (millions) |
| Market Capitalization: $0.24 (millions) |
| Beta: -1.35 |
| 52 Week High: $0.00 |
| 52 Week Low: $0.00 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
0.00% |
-5.03% |
| 12 Week |
0.00% |
-12.90% |
| Year To Date |
% |
% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
6320 CANOGA AVENUE 15TH FLOOR
-
WOODLAND HILLS,CA 91367
USA |
ph: 800-701-1223
fax: 818-230-9899 |
sbarnes@endonovo.com |
http://www.endonovo.com |
|
|
| |
| • General Corporate Information |
Officers
Alan Collier - Chief Executive Officer;Chairman; Chief Financial
Ira Weisberg - President; Chief Commercial Officer Medical divisi
- - -
- - -
- - -
|
|
Peer Information
Endonovo Therapeutics, Inc. (CORR.)
Endonovo Therapeutics, Inc. (RSPI)
Endonovo Therapeutics, Inc. (CGXP)
Endonovo Therapeutics, Inc. (BGEN)
Endonovo Therapeutics, Inc. (GTBP)
Endonovo Therapeutics, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 29272H300
SIC: 3845
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/24
Next Expected EPS Date: 08/28/25
|
|
Share - Related Items
Shares Outstanding: 1,206.61
Most Recent Split Date: 12.00 (0.00:1)
Beta: -1.35
Market Capitalization: $0.24 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $ |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/28/25 |
|
|
|
| |
